In patients with neither MUC16 or TTN mutations, ALM patients (HR: 1.92; CI: 1.05–3.52; p = 0.0352) or MUP patients (HR: 2.25; CI: 1.82–2.77; p < 0.001) had worse prognosis than CM patients. The gene discussed is MUC16; the disease is acral lentiginous melanoma.